JP2005501524A - アポトーシスを調節する薬剤 - Google Patents

アポトーシスを調節する薬剤 Download PDF

Info

Publication number
JP2005501524A
JP2005501524A JP2002589706A JP2002589706A JP2005501524A JP 2005501524 A JP2005501524 A JP 2005501524A JP 2002589706 A JP2002589706 A JP 2002589706A JP 2002589706 A JP2002589706 A JP 2002589706A JP 2005501524 A JP2005501524 A JP 2005501524A
Authority
JP
Japan
Prior art keywords
seq
apoptosis
molecule
cell
ribozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002589706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501524A5 (enExample
Inventor
リチャード トリツ，
ベンジャミン ケイリー，
セリア ハビタ，
ジョアン ロビンズ，
ジャック バーバー，
Original Assignee
イミューソル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューソル インコーポレイテッド filed Critical イミューソル インコーポレイテッド
Publication of JP2005501524A publication Critical patent/JP2005501524A/ja
Publication of JP2005501524A5 publication Critical patent/JP2005501524A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2002589706A 2001-05-14 2002-05-14 アポトーシスを調節する薬剤 Pending JP2005501524A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29092701P 2001-05-14 2001-05-14
PCT/US2002/015198 WO2002092840A2 (en) 2001-05-14 2002-05-14 Agents that regulate apoptosis

Publications (2)

Publication Number Publication Date
JP2005501524A true JP2005501524A (ja) 2005-01-20
JP2005501524A5 JP2005501524A5 (enExample) 2006-01-05

Family

ID=23118085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589706A Pending JP2005501524A (ja) 2001-05-14 2002-05-14 アポトーシスを調節する薬剤

Country Status (6)

Country Link
US (1) US20040248830A1 (enExample)
EP (1) EP1474175A4 (enExample)
JP (1) JP2005501524A (enExample)
AU (1) AU2002314780A1 (enExample)
CA (1) CA2446991A1 (enExample)
WO (1) WO2002092840A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011129371A1 (ja) * 2010-04-14 2011-10-20 国立大学法人鳥取大学 ５－ＦＵ単独及びＩＦＮ－α／５－ＦＵ併用時の抗腫瘍効果を増強する遺伝子群

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677739A4 (en) * 2003-09-04 2008-07-23 Immusol Inc METHODS FOR IDENTIFYING AGENTS THAT INHIBIT THE GROWTH OF CANCER CELLS
US8012948B2 (en) * 2008-10-15 2011-09-06 Promising Future, Llc Fas/FasL or other death receptor targeted methods and compositions for killing tumor cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996741A4 (en) * 1997-01-23 2004-06-09 Immusol Inc FUNCTIONAL ANALYSIS AND GENE DISCOVERY USING TARGET SPECIFIC RIBOZY VECTOR BANKS OR WELL MADE RANDOM

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011129371A1 (ja) * 2010-04-14 2011-10-20 国立大学法人鳥取大学 ５－ＦＵ単独及びＩＦＮ－α／５－ＦＵ併用時の抗腫瘍効果を増強する遺伝子群

Also Published As

Publication number Publication date
AU2002314780A1 (en) 2002-11-25
US20040248830A1 (en) 2004-12-09
CA2446991A1 (en) 2002-11-21
EP1474175A2 (en) 2004-11-10
EP1474175A4 (en) 2005-01-19
WO2002092840A3 (en) 2004-09-10
WO2002092840A2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
AU2012352153B2 (en) Cancer diagnostics using non-coding transcripts
KR101944555B1 (ko) 유방암 전이의 진단, 예후 및 치료 방법
WO2020081556A2 (en) Non-canonical swi/snf complex and uses thereof
US20050208486A1 (en) Brca-1 regulators and methods of use
CA2848369A1 (en) Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
WO1999033963A1 (en) Metastatic cancer regulated gene
US20070243176A1 (en) Human genes and gene expression products
CA2814598A1 (en) Recurrent gene fusions in prostate cancer
WO2002101357A9 (en) Molecular signatures of commonly fatal carcinomas
KR20110084995A (ko) 전립선암에서의 반복적 유전자 융합체
JP2011254830A (ja) 結腸癌に関するポリヌクレオチド
WO1999064594A2 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO2021162981A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
JP2002525081A (ja) 低酸素により調節される遺伝子転写に特徴的な配列
US8076061B2 (en) Method and composition for cancer diagnosis and treatment
US7348418B2 (en) Carcinoma-related genes and polypeptides and methods of use thereof
JP6519927B2 (ja) 癌の診断、阻害剤のスクリーニングにおけるｒｈｏａの使用
JP2005501524A (ja) アポトーシスを調節する薬剤
AU2010201655A1 (en) Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
WO2016104794A1 (ja) Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測
JP2003528630A (ja) ヒト遺伝子および発現産物
KR101083562B1 (ko) Ｆｌｊ２５４１６ 유전자의 신규한 용도
US7785813B2 (en) Prefoldin 4 in the treatment and diagnosis of cancer
EP3930729A1 (en) Diagnosis and treatment of medulloblastoma
EP1365032B1 (en) Marker molecules associated with lung tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080806